[Treatment of ulcers with pirenzepin. Results from clinic and practice].
In two studies the beneficial effect of Pirenzepine in the treatment of peptic duodenal and gastric ulcers was investigated in 1686 outpatients. Study 1 includes patients treated and controlled mainly in hospitals, in study 2 treatment and control was performed mainly by practitioners. After four weeks of treatment healing of duodenal ulcers was observed in 68% of the patients in study 1 and 66% in study 2. Healing of peptic gastric ulcers was observed in 62% of the patients in study 1 and 53% of the patients in study 2. Mild anticholinergic side effects were observed in approximately 10% of the patients. Healing rates under Pirenzepine are similar those reported for Cimetidin or Carbenoxolon. It is concluded that Pirenzepine has a beneficial effect in the treatment of peptic duodenal and gastric ulcer disease.
D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001570:Benzodiazepinones / Q000627:therapeutic use*; D002229:Carbenoxolone / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D002927:Cimetidine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004381:Duodenal Ulcer / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy*; D010890:Pirenzepine; D013276:Stomach Ulcer / Q000188:drug therapy
D000897:Anti-Ulcer Agents; D001570:Benzodiazepinones; D010890:Pirenzepine; D002927:Cimetidine; D002229:Carbenoxolone
Ulkusbehandlung mit Pirenzepin. Ergebnisse aus Klinik und Praxis.